Enable Injections is a Cincinnati, OH-based healthcare company focused on improving the patient treatment experience with its enFuse On-Body Delivery System (OBDS), which enables subcutaneous administration of large-volume drugs. The technology aims to replace lengthy intravenous infusions with a discreet, wearable device that patients can use outside clinical settings. To scale production, the company announced plans in February 2024 for a 90,000-square-foot Manufacturing Center of Excellence in Springdale, Ohio, alongside upgrades to its Evendale headquarters. Enable Injections closed a $215 million Series C round in January 2022 led by Magnetar Capital, with participation from Sanofi and other institutional and regional investors. In January 2026, Sanofi committed an additional $30 million, underscoring strategic support for the commercialization of enFuse. The new capital will be used to consolidate supply-chain capabilities and accelerate commercial growth. These funds position Enable Injections to advance toward full-scale manufacturing and market launch of its OBDS platform.

Total raised

$275M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2026